Department of Dermatology, Saint-Pierre and Brugmann University Hospitals, Université Libre de Bruxelles, Brussels, Belgium.
Int J STD AIDS. 2024 Nov;35(13):1084-1086. doi: 10.1177/09564624241279489. Epub 2024 Sep 3.
Psoriasis, a chronic inflammatory skin disease, presents unique challenges when co-occurring with HIV. Tildrakizumab, an IL-23p19 inhibitor, has demonstrated efficacy in treating moderate-to-severe psoriasis. This retrospective case series reports three individuals living with HIV and psoriasis treated with tildrakizumab. Clinical outcomes, including Psoriasis Area and Severity Index (PASI) and HIV viral load, were recorded over a year. All three patients achieved significant clinical improvements with tildrakizumab, with PASI scores improving by over 95%. No adverse effects were reported, and HIV viral loads remained undetectable. Tildrakizumab appears to be a safe and effective treatment option for psoriasis in individuals living with HIV, providing significant benefits without compromising HIV control.
银屑病是一种慢性炎症性皮肤病，与 HIV 同时存在时会带来独特的挑战。IL-23p19 抑制剂特诺雅（tildrakizumab）在治疗中重度银屑病方面已被证明具有疗效。本回顾性病例系列报告了 3 名 HIV 合并银屑病患者接受特诺雅治疗的情况。记录了一年多来的临床结局，包括银屑病面积和严重程度指数（PASI）和 HIV 病毒载量。所有 3 名患者均通过特诺雅治疗获得了显著的临床改善，PASI 评分改善超过 95%。未报告不良反应，HIV 病毒载量仍无法检测到。特诺雅似乎是 HIV 感染者银屑病的一种安全有效的治疗选择，在不影响 HIV 控制的情况下提供了显著的益处。
